JP2021522784A5 - - Google Patents
Info
- Publication number
- JP2021522784A5 JP2021522784A5 JP2020560920A JP2020560920A JP2021522784A5 JP 2021522784 A5 JP2021522784 A5 JP 2021522784A5 JP 2020560920 A JP2020560920 A JP 2020560920A JP 2020560920 A JP2020560920 A JP 2020560920A JP 2021522784 A5 JP2021522784 A5 JP 2021522784A5
- Authority
- JP
- Japan
- Prior art keywords
- scvacv
- virus
- item
- clone
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024028557A JP2024051112A (ja) | 2018-05-02 | 2024-02-28 | 合成キメラワクシニアウイルス |
| JP2025151400A JP2025178289A (ja) | 2018-05-02 | 2025-09-11 | 合成キメラワクシニアウイルス |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862665973P | 2018-05-02 | 2018-05-02 | |
| US62/665,973 | 2018-05-02 | ||
| PCT/US2019/030486 WO2019213452A1 (en) | 2018-05-02 | 2019-05-02 | Synthetic chimeric vaccinia virus |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024028557A Division JP2024051112A (ja) | 2018-05-02 | 2024-02-28 | 合成キメラワクシニアウイルス |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021522784A JP2021522784A (ja) | 2021-09-02 |
| JP2021522784A5 true JP2021522784A5 (enExample) | 2022-05-12 |
Family
ID=68386164
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020560920A Withdrawn JP2021522784A (ja) | 2018-05-02 | 2019-05-02 | 合成キメラワクシニアウイルス |
| JP2024028557A Pending JP2024051112A (ja) | 2018-05-02 | 2024-02-28 | 合成キメラワクシニアウイルス |
| JP2025151400A Pending JP2025178289A (ja) | 2018-05-02 | 2025-09-11 | 合成キメラワクシニアウイルス |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024028557A Pending JP2024051112A (ja) | 2018-05-02 | 2024-02-28 | 合成キメラワクシニアウイルス |
| JP2025151400A Pending JP2025178289A (ja) | 2018-05-02 | 2025-09-11 | 合成キメラワクシニアウイルス |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12529036B2 (enExample) |
| EP (1) | EP3788142A4 (enExample) |
| JP (3) | JP2021522784A (enExample) |
| CN (2) | CN112543806B (enExample) |
| AR (1) | AR115069A1 (enExample) |
| AU (1) | AU2019262149B2 (enExample) |
| BR (1) | BR112020022181A2 (enExample) |
| CA (1) | CA3099330A1 (enExample) |
| MX (1) | MX2020011586A (enExample) |
| SG (1) | SG11202010272PA (enExample) |
| TW (1) | TW201946651A (enExample) |
| WO (1) | WO2019213452A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3535389A4 (en) | 2016-11-02 | 2020-06-03 | David Evans | SYNTHETIC CHIMERIC POCKET VIRUS |
| JP7551496B2 (ja) | 2017-10-31 | 2024-09-17 | カリヴィル イムノセラピューティクス， インコーポレイテッド | 全身送達のためのプラットフォーム腫瘍溶解性ベクター |
| SG11202010272PA (en) | 2018-05-02 | 2020-11-27 | David Evans | Synthetic chimeric vaccinia virus |
| MX2022009200A (es) * | 2020-02-03 | 2023-01-04 | Vectores a base de poxvirus producidos por acido desoxirribonucleico (adn) natural o sintetico y usos de los mismos. | |
| TWI902763B (zh) * | 2020-02-26 | 2025-11-01 | 加拿大亞伯大州立大學理事會 | 基於重組痘病毒之抗SARS-CoV-2病毒疫苗 |
| EP4153228A4 (en) | 2020-05-17 | 2024-07-10 | City of Hope | CORONAVIRUS VACCINES BASED ON SYNTHETIC MODIFIED ANKARA VACCINE (SMVA) VIRUS |
| PE20231175A1 (es) | 2020-11-19 | 2023-08-01 | Kalivir Immunotherapeutics Inc | Inmunoterapia oncolitica por remodelacion del microambiente tumoral |
| CA3206004A1 (en) | 2021-02-02 | 2022-08-11 | Mary Jo Hauser | Viral constructs for use in enhancing t-cell priming during vaccination |
| IL316712B2 (en) * | 2021-04-30 | 2025-12-01 | Kalivir Immunotherapeutics Inc | Oncolytic viruses for modified mhc expression |
| WO2023168286A1 (en) | 2022-03-01 | 2023-09-07 | Tonix Pharmaceuticals Holding Corp. | Recombinant poxvirus based vaccine against the omicron strain of sars-cov-2 virus and variants thereof |
| CN116042656A (zh) * | 2022-11-25 | 2023-05-02 | 中山大学附属第七医院(深圳) | 一种猴痘病毒mRNA疫苗及其制备方法与用途 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2787577A (en) | 1953-12-01 | 1957-04-02 | Lilly Co Eli | Stable smallpox vaccine |
| US4754065A (en) | 1984-12-18 | 1988-06-28 | Cetus Corporation | Precursor to nucleic acid probe |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| US6004777A (en) | 1997-03-12 | 1999-12-21 | Virogenetics Corporation | Vectors having enhanced expression, and methods of making and uses thereof |
| US6723325B1 (en) | 2001-04-23 | 2004-04-20 | Acambis, Inc. | Smallpox vaccine |
| US20040014034A1 (en) * | 2002-06-06 | 2004-01-22 | Evans David H | Method of producing a recombinant virus |
| AU2004269320B2 (en) | 2003-06-20 | 2009-12-24 | Protein Sciences Corporation | Vectors expressing SARS immunogens, compositions containing such vectors or expression products thereof, methods and assays for making and using |
| WO2005028634A2 (en) | 2003-09-18 | 2005-03-31 | Emory University | Improved mva vaccines |
| WO2005103259A1 (en) | 2004-04-26 | 2005-11-03 | University Health Network | Sars-cov nucleocapsid protein epitopes and uses thereof |
| JPWO2006022215A1 (ja) | 2004-08-23 | 2008-05-08 | 財団法人ヒューマンサイエンス振興財団 | ＳＡＲＳ−コロナウイルスタンパク質をコードするＤＮＡを保有する組換えワクチニアウイルスＤＩｓ株、およびその利用 |
| CN101020055B (zh) | 2006-02-16 | 2012-08-08 | 中国疾病预防控制中心性病艾滋病预防控制中心 | 基于复制型痘苗病毒载体的sars疫苗 |
| WO2008100292A2 (en) | 2006-10-16 | 2008-08-21 | Genelux Corporation | Modified vaccinia virus strains for use in diagnostic and therapeutic methods |
| WO2009117030A2 (en) | 2007-12-19 | 2009-09-24 | Macrogenics, Inc. | Improved compositions for the prevention and treatment of smallpox |
| CN114262690A (zh) * | 2011-04-15 | 2022-04-01 | 吉恩勒克斯公司 | 减毒的痘苗病毒的克隆毒株及其使用方法 |
| FI20115914A7 (fi) * | 2011-09-16 | 2013-03-17 | Oncos Therapeutics Ltd | Muunnettu onkolyyttinen virus |
| WO2014160475A1 (en) | 2013-03-13 | 2014-10-02 | Aboody Karen S | Tropic cell based virotherapy for the treatment of cancer |
| ES2768292T3 (es) | 2013-04-10 | 2020-06-22 | Tot Shanghai R&D Center Co Ltd | Cepas de virus vaccinia mutante, usos de estas y método para producirlas |
| EP3045181B1 (en) | 2015-01-19 | 2018-11-14 | Ludwig-Maximilians-Universität München | A novel vaccine against the middle east respiratory syndrome coronavirus (MERS-CoV) |
| EA201800148A1 (ru) | 2015-08-11 | 2019-01-31 | Калиди Биотерапьютикс, Инк. | Оспенная вакцина для лечения рака |
| JP2018533547A (ja) | 2015-09-16 | 2018-11-15 | 株式会社新日本科学 | ワクチン組成物 |
| WO2018057755A1 (en) | 2016-09-21 | 2018-03-29 | Thorne Stephen H | High mobility group box i mutant |
| EP3535389A4 (en) * | 2016-11-02 | 2020-06-03 | David Evans | SYNTHETIC CHIMERIC POCKET VIRUS |
| ES2702618B2 (es) | 2017-09-04 | 2019-10-31 | Inst De Salud Carlos Iii | Producto de combinación que comprende una célula madre mesenquimatosa modificada y una sustancia antigénica. |
| EP3787681A4 (en) * | 2018-05-02 | 2022-01-19 | Tonix Pharma Holdings Limited | Stem cells comprising synthetic chimeric vaccinia virus and methods of using them |
| SG11202010272PA (en) | 2018-05-02 | 2020-11-27 | David Evans | Synthetic chimeric vaccinia virus |
-
2019
- 2019-05-02 SG SG11202010272PA patent/SG11202010272PA/en unknown
- 2019-05-02 MX MX2020011586A patent/MX2020011586A/es unknown
- 2019-05-02 AU AU2019262149A patent/AU2019262149B2/en active Active
- 2019-05-02 EP EP19796145.1A patent/EP3788142A4/en active Pending
- 2019-05-02 JP JP2020560920A patent/JP2021522784A/ja not_active Withdrawn
- 2019-05-02 BR BR112020022181-3A patent/BR112020022181A2/pt unknown
- 2019-05-02 CN CN201980029677.9A patent/CN112543806B/zh active Active
- 2019-05-02 WO PCT/US2019/030486 patent/WO2019213452A1/en not_active Ceased
- 2019-05-02 CN CN202510639606.8A patent/CN121320271A/zh active Pending
- 2019-05-02 US US17/050,946 patent/US12529036B2/en active Active
- 2019-05-02 CA CA3099330A patent/CA3099330A1/en active Pending
- 2019-05-02 TW TW108115290A patent/TW201946651A/zh unknown
- 2019-05-02 AR ARP190101165A patent/AR115069A1/es unknown
-
2024
- 2024-02-28 JP JP2024028557A patent/JP2024051112A/ja active Pending
-
2025
- 2025-09-11 JP JP2025151400A patent/JP2025178289A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019535311A5 (enExample) | ||
| CA2421151C (en) | Modified vaccinia ankara virus variant | |
| Afonso et al. | The genome of swinepox virus | |
| US12365879B2 (en) | Synthetic chimeric poxviruses | |
| JP2023515582A5 (enExample) | ||
| AU2002231639A1 (en) | Modified vaccinia ankara virus variant | |
| BR112020022181A2 (pt) | vírus vaccinia quimérico sintético | |
| JP2020188776A (ja) | 組換えオルフウイルスベクター | |
| Zhang et al. | Genomic sequence and virulence of clonal isolates of vaccinia virus Tiantan, the Chinese smallpox vaccine strain | |
| CN105829537A (zh) | 用于使用痘病毒载体诱导增强的免疫应答的组合物和方法载体 | |
| JP2019528755A5 (enExample) | ||
| EP4396333A1 (en) | Utilization of micro-rna for downregulation of cytotoxic transgene expression by modified vaccinia virus ankara (mva) | |
| JP2024535145A5 (enExample) | ||
| CA2372709C (en) | Vector for integration of heterologous sequences into poxviral genomes | |
| EP1594970B1 (en) | Recombinant mva and method for generation thereof | |
| CN101142319B (zh) | 基于使用修饰安卡拉痘苗病毒的疫苗 | |
| JP2021522789A5 (enExample) | ||
| Wang et al. | Characterization of an attenuated TE3L-deficient vaccinia virus Tian Tan strain | |
| Kan et al. | Generation of an attenuated Tiantan vaccinia virus by deletion of the ribonucleotide reductase large subunit | |
| Li et al. | Deletion of multiple genes induces virulence reduction of vaccinia virus Tiantan strain | |
| Spread | Genome Scale Evolution of Myxoma Virus | |
| Maksyutov et al. | Construction of a Candidate DNA Vaccine against Human Orthopoxvirus Infections | |
| Qin | Using genomic sequencing to explore vaccinia virus diversity, recombination and evolution | |
| Stanford et al. | The Th 1/Th 2 paradigm | |
| NZ752893B2 (en) | Synthetic chimeric poxviruses |